


For Across the Spectrum of NVAF Patients

Apixagress

Apixaban 2.5 Mg & 5 Mg Tablets



For Across the Spectrum of NVAF Patients

Apixagress

Apixaban 2.5 Mg & 5 Mg Tablets

Description:

Apixagress is available as film coated tablet of Apixaban, in two strengths i.e 2.5 mg & 5 mg.

Indication:

- Reduce the risk of stroke and systemic embolism resulting from nonvalvular atrial fibrillation.
- For the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE).
- For the treatment of DVT and PE and the reduction in risk of DVT and PE following initial therapy.

Mechanism of Action:

Apixaban is an orally available Factor Xa antagonist.

- Apixaban inhibits free and clot-bound FXa, and prothrombinase activity.
- Apixaban has no direct effect on platelet aggregation.
- By inhibiting FXa, apixaban decreases thrombin generation and thrombus development.

Dosage and Administration:

Prophylaxis of DVT: The recommended dose is 2.5 mg orally twice daily.

Patients with NVAF: The recommended dose is 5 mg orally twice daily.

Treatment of DVT & PE: The recommended dose is 10 mg orally twice daily.

Presentation:

Apixagress is available as 10 tablets in a stip.

 ${\sf DVT: Deep\ vein\ thrombosis, PE: Pulmonary\ Embolism, NVAF: Nonvalvular\ atrial\ fibrillation.}$

Reference: ® Hospital Practice, Volume 39, Issue 4, October 2011, ISSN – 2154-8331

La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads, S.G. Highway, Ahmedabad-380015, Gujarat, India. Phone: +91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998 E-mail: info@larenon.com | Web: www.larenon.com

